Group Walters Buys 4,335,000 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) major shareholder Group Walters bought 4,335,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the transaction, the insider owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Zentalis Pharmaceuticals Stock Up 0.5%

ZNTL stock opened at $3.84 on Friday. The firm has a 50 day moving average of $4.35 and a two-hundred day moving average of $3.67. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.21 and a 12 month high of $6.95. The company has a market capitalization of $275.21 million, a price-to-earnings ratio of -1.97 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZNTL has been the subject of a number of research reports. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Mizuho initiated coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price for the company. Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.75.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth about $1,815,000. Seven Fleet Capital Management LP bought a new position in Zentalis Pharmaceuticals during the 1st quarter valued at about $257,000. Anfield Capital Management LLC lifted its holdings in Zentalis Pharmaceuticals by 239.9% during the 4th quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock valued at $328,000 after purchasing an additional 171,228 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Zentalis Pharmaceuticals by 182.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock valued at $634,000 after purchasing an additional 175,771 shares during the last quarter. Finally, 5AM Venture Management LLC boosted its position in Zentalis Pharmaceuticals by 705.7% in the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after buying an additional 3,457,913 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.